-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NpGvklOqH3uRr6QY17CizLYxDnBOKpix/t7yCfO2FRZ4jSFNQ7SDZHqi+6YYgrBj
 +LurQD80TkQ3yY+Kg0jguw==

<SEC-DOCUMENT>0001193125-10-118453.txt : 20100513
<SEC-HEADER>0001193125-10-118453.hdr.sgml : 20100513
<ACCEPTANCE-DATETIME>20100513101602
ACCESSION NUMBER:		0001193125-10-118453
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100512
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100513
DATE AS OF CHANGE:		20100513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		10826840

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): May&nbsp;13, 2010 (May 12, 2010) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>On
May&nbsp;13, 2010, ARCA biopharma, Inc. issued a press release announcing that it received notification from the NASDAQ Stock Market that the Company has demonstrated compliance with the minimum stockholders&#146; equity requirement for the NASDAQ
Global Market set forth in Listing Rule 5450(b)(1)(A) and that the Company is in compliance with all applicable requirements for continued listing on the NASDAQ Global Market. The press release is attached as Exhibit&nbsp;99.1 hereto, the contents
of which are incorporated herein by reference. <B> </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA Regains NASDAQ Listing Compliance&#148;, dated May 13, 2010.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May&nbsp;13, 2010 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Patrick M. Wheeler</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patrick M. Wheeler</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acting Chief Financial Officer</FONT></TD></TR></TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA Regains NASDAQ Listing Compliance&#148;, dated May 13, 2010.</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g41507g49k74.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor
Relations&nbsp;&amp; Corporate Communications </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com </U></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA Regains NASDAQ Listing Compliance </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, May&nbsp;13, 2010</I> &#150; ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically targeted
therapies for heart failure and other cardiovascular disease, today announced that it received notification from the NASDAQ Stock Market that the Company has demonstrated compliance with the minimum stockholders&#146; equity requirement for the
NASDAQ Global Market set forth in Listing Rule 5450(b)(1)(A) and that ARCA is in compliance with all applicable requirements for continued listing on the NASDAQ Global Market. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is
dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company&#146;s lead product candidate, bucindolol hydrochloride, is an investigational, pharmacologically unique beta-blocker and mild
vasodilator being developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to bucindolol, giving it the potential to be the first genetically-targeted heart failure treatment.
ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for bucindolol. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press
release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management&#146;s current expectations and involve risks and
uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. These factors are identified and described in more detail in ARCA&#146;s filings with the SEC,
including without limitation, the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2009, the Company&#146;s quarterly report on Form 10-Q for the period ended March&nbsp;31, 2010 and subsequent filings. The Company
disclaims any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g41507g49k74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g41507g49k74.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4P#A`P$1``(1`0,1`?_$`,H```$#!0$!````````
M```````'"0H!`P4&"`0"`0$!``$%`0$!`````````````0(#!08'"`D$"A``
M``8!`P("!@<$!P8'`````0(#!`4&!P`1"!(3(0DQ89$B%!5!48$RLC,6<4(C
M"K%2)':W&#FA\9)3-W?!T50E-A=7$0`!`P($!`($!!$)"0`````!``(#$00A
M$@4&,4$3!V$B47$R"(&1%`FAL=%"4F)RDM(C8Y.S%546&,&RPC-$E+0V5D.#
M)#1DI'65%__:``P#`0`"$0,1`#\`G[F$"@(CZ`_W:(DGR-G'%N*"I%O-M81+
MUPEWFL0F1Q(S3E+QZ54XJ.1=/"('$!`JBA2)B(;=6^NH^YG??M1VA:QN_M9M
MK.^E;FCMVYYKE[?LFV\+7RAIX![FM82",U5R#1=K:]N$G]4VSY(FFA>:-8#Z
M"]Q#:^`)/@D/#G?Q_,(@61MAMAV]VHR8_P#A].N@3\X'[N8_M6KT_P#'S+EG
M_P`EWAQR6_YYJ]!><>"#E,<KNWB4@`8X_I&2]T#&`H"._CL)C`&JWYP'W=7M
M<YEQK!:T`D_J^?`$@#Z)`^%8'M3NX&A;;5/Y9JLGYV8"3^^^MQ?6-1D]8CYP
M3W<CPNM7_P#7SK(=IMWG@RV_/-6VT[E]@2Z2",4RN7R>0<JE1:HV>-?0"3E4
MX[$32?/42QQ3G-X%*=8IC".P`(ZYQLGWRO=[WSJ4>D6&N"RU*5X;&R^AEM`]
MQX!LLK1#4\`'2`DX`$X+;=3[<[NTJ$W$UKU(6BI,3FR4'BUIS?$"NE>\3P$!
M$0$`$!#Q`0$-P$!#P$!#7J($$5&(7!D=XGK]FJB.\3U^S1$=XGK]FB*O=('I
MZ@W\0\/H^O1%3O$]?LT1'>)Z_9HB.\3U^S1$=XGK]FB([Q/7[-$1WB>OV:(C
MO$]?LT1'>)Z_9HBJ"I1]'4/["B.B*O6']4__``CHB^>\3U^S1$=XGK]FB([Q
M/7[-$505(/@'4(_4`;Z(J=XGK]FB([Q/7[-$5PH@8`$/0/\`NT15T1)MF"]!
MC/&5TO/8(Y6KT*NZ9-E-^TO)K'39122NWCV3R+E(#[>/1OKK/O)W`;VL[7:W
MO_()9M-L7R1,/LOG<1'`UWVKIGQAU,<M:8K>MN:2==URVTFN5LTH#CS#1YGD
M>(:#3Q4?-RZGK[8W\Y/22TG-SCQ1W(R;TXB9R[6-OL8X^XW0)N!$RALFD0`*
M'24/#^;_`%35=P[\W-/K.NW3[O<FHSF2:>4^W(X\SP8P>RQHI'&T-:`U@P]C
M1Q6>CV++6T8([2)M&M:.`'TSS)XDU.)2W4?%BCZ31B7Z!FRC]0(X>^02"V>K
M])6*B@&V$I2O!3`P^CMF$?1KNWMWV7N=6U1NE:TUT3[EW0.<9>G*XCHD@\`)
M<F8\,CG$8$%<2UC<C(83<0',UGFPYM'M4^"M/$!*Q$X<$8NW"X9'1<0\<T%=
M)1/8Z3@;!',EDC`/B4Z?4<!#U#KNS1NPEJ-(UH7,!;<V5K'G:6XL?\L@C<".
M-1Y@?45QJXW2[Y1;Y'U9(\TIP(Z;C7Z2TZQXC".@FKY1$2+S:C@[,@EV,$7'
MJ=I5T(#^Z[D!$A!^D&YOKUP/=78ANF;<CU"-I;=7[G&,4H?D\+LKGT]$DWE:
M>8A=R*W.PW09KPQ5\D0%?NW8@?`W$_=!<Z66H.X4"'71%(K@O<224*/6H@;<
M2KB00]Q%7]P1^^'B&X>.O,6XMJZEMMS6ZDPMCE%6-</,6'@\CDQWUI/M\6U;
MBN=V&I17>##4MP)\?1ZQS]'/%.?\#LL3%MJUAQW87B\@[HQ8]W`O72AUG(UN
M1,NW"-56.(G4)$/6_2B)A$2HK%)Z"%U]=OF]N\.M;QVEJ/;;<<\ES=Z!T9+2
M5Y+GFRFSL$+G'%PMY(R(R22(Y&LX,"Z$[N[=MM.U"'6K-H9'=YA(T8#JMH<P
M'+.#4_;`GB2N_-?19=/(T1(ER1SC6.-6!\K9WN!D_D>,:;+64[4Y^V,M)H(_
M#P$`@;_U5@GG#9DD'_,7#14"IHF1?(6YTY!Y&L^1&(\VW.6N&1XFVN,WUF1G
M)!U).?TA?I`6UIKD6J[64,U@*=:@1%FU3V2;-I,B9`*0@!HLG@#$*1/HL%:7
M3,L@NB599L99%5(KAN)"N&YE$S$*N@90BJ8+(B;J*)BF+U`&X"'AHBCH^8[1
MN?/!W!TMR+PYYB>:;U5J[9*]%6BE95J6*Y669Q]IEV\''2<+8HZF-&SL64H]
M1(NW69)]21Q.50!)T&JU`03P2&>61:/,5\R&'RE<KMY@V2\44K&\_#55)I0<
M?XL/9+!/2D6,TN;XQS5F[&'BHY@=$-P275755$`Z`)N8ARMY+LCE'@SS,N*&
M)[;GCCSS\R#GE/&T,_M=RQ3G+&F,IIQ+U.'1%W//JW*P]?9"L]B(Q-5T=F8C
M=19%$_97!7H(>*`M.!"4;RI_-=8<^&UBQMD6L1%#S]1X%&RO&M=7<&I^0*H#
MMO&NK+5V\BNXD8E]%/W:!'\<JLY!(KA-5)8Y#'*D4<VG#@GF-%BF1?,%\XVK
M\9[U_EOXWTHG(+E$]D&%=7A&HO'E/I-FF%4F\76Y1.$,,O;[PX673#Y*P.B*
M`G*#ERB?^&)9AM<3P60Q!PGY\9YBV=^YV\Y<R4%]/-TG8\?>*\I"8G@JJU73
M*JC$6*ZP4:X?2<DW`W0NFU%4$S`(`]7'W]7U)F`P:$J%N\JJ(6BESXEYK<],
M17`A!-'60O)&Y7^,(ZV]U66K5L<JDD$!.`"=-!TS,(;@!@U%,W@$VUQZNOF2
M<2/,WP+QFY?<@[GEO#67OUW'4VRR"K&3I^12H4J>=0KIH_?11;##V2`GVK4K
MV-5="J@=8ANI=!5)4]61REM0I/\`J+31HBCW>?CSAN/'K'6)\&X9NTO2LM9(
ML+;(TW/5J4<Q4W!8_H4BFM&-?BF:B3A-M<;DFDF<H&Z'#.-=(G`R:A@&A9L%
M<2GDN*V=(CDQQSPUG>&,@".2Z'!S\BV;;]J,LGPX,;9"["(F*:%L[-VU$!\=
MT=18D4-$O^BB]B7Y9?M_$.B*YHBYGYAAU<<<E`'I%I!![;5!Z\M>^F:>[+N@
M_D+7_'VJYSVV_P`ZV/W4GZ*1-18OJ<?**(E._1CUC"4"C)$5^!,.WB(O6R:Q
MD.HW_,2`@?2?7QU[-[+TO<%TV::X9;7#B/Z]IZ1_WL8<6>I\8:.;UZ`W%J4U
MLTY6%[/M:9OO217X#7P3AM<HJ3.MJK7IN$2QA(TS^'OC-5M(,V[-J`&+'/G+
M)9=*2:";8&@=7?(H()$'82E#Z=[;V%':[9?)O^/Y%IMA:F:UU:)T<T3(H\1#
M+)$]S9HR:"WQZS7D1,)#FL'2EYJKI+T#2CU)I7Y7P$%KBX_7-!`RG[/ZTCS'
M@2MVC;3$W!Q.'C*DX.VLK5FUE'CE^1DZ??"&*H5\DT2:N2,G#I4@',!E%!W`
M-]AWUS;3MW:+O.[U$Z3HLKK;58HH[B1TPBDEZ1KU6Q-CD$3WNHYP<]Y)`)\U
M:[7/87&G,B$]P,\!):`W,UN;D7$C,!PX!9.RU*-FC*3+2"<2TG&L8Z&@Z>+4
M#,HL$$5`2?20@?I?QZ*O6<I?<(HH(%4#Q'6[;GVCI>MO?KUCI\MYJ]K;P6UK
MIA96.WR-.66:AI+"UV9P'E8]Y#90:D+1LM0FM@+:65L<#WN>^:OF=4XAOV+C
M@.9`Q:N#\N4-9FL]<V.29!++'45<,VRR4M)@K]3H&1_E[$?#8"'7`Q"AL!-@
M`-?//OEVVDAZ]]N>ZA&M.+G211N;<3YOM^D>C%Z,KI06``".@`7;6V=8:\-C
MLF.-N.!(+&T\*^9WK#:'TK:N`;<K;)>2TR%,4GZ.C1*!Q`3>$Z4!WZ2E+X_L
M\-<N^;;8R+N7NF)@<&-T>`#,03_S)XT`'T,/'BOR]X7F30K%YX_*7?S$ZKK[
M#+SVC1$SMSUDTN3/+CB%Y><<))&INK`CRNY0-"E%=H.*<3/#N:+3)P$A,!&-
M[O*!$UD5`#J*D@/H.&Y9#`$J/LP=*>53YS[I)430N)SY,59N"AU%8J<?\]&3
M<-5.DHD35:T9Q)I'VWV*O!"'@(;:JS]IJG)`)3`!B&`Y#`!B'*("4Y#!N4Y1
M`1`2F*.X"'@(:BTD:(FB?/0_TT\V_P!X<2?XH5;19-]I<4?RU7_0'DQ_WLKO
M^'T7JE9/Y)^_D%9Z[2\#9JMMM<-6M8KN*,@RTZL]4(FV^6LZI*J.45#*"!3"
MY(';*7Q$YS@4`$1`-18#BH:_\O1BN\VKFZ7)\-'NTJ+B3%EO2O$P)%21Q7]X
MC48*L5<S@"]E:4?.04>E0W$P(,#J"`>Z(U:C_94G_P`T+E=(\.>&N2\J5A=-
MOD29-'8XQ>LH0JI6=WNAEV;6:[1Q`JIJQ$(/)0I!`Q3G9E*8!*8=18-%2F&O
MY=_C`PR+DK+_`#%R"@K9)+'<F%(Q\_G!4D7*F1K<R4GK_=UW;HQSNK`T@I)N
MW(X.)C]<JY/OU["%63SA12[-1::-$2(YDX_8^SG(X?F;HE*(3>#,M5O,V/IF
M#=-F,G'VFN)/6GP#ETX9/3+UR>CY!5M)-"]L7*(EV.0Q2F`J#1+</L_9HHK+
MAPW:(+NW:Z35HU15<NG*ZA$D&S9`AE5W"ZJABD2112()C&$0`I0$1T119KWQ
MW6\S3C_YD/.$8HTG-V2P)5WAGWTC_%L\3\4'#Q=TXADS]SLFR\^^:I*ID$!.
MX'VU:E<I`6T?RX')D)VAY@XH3D@)WE*D$\PXX07.(G/5+4LA%W>-;`<VY4(>
MT%:/.@`^]+*#]`Z%1XYJ3OJ+!>Q+\LOV_B'1%<T1<V<O!*'';(PG`1+\-`=0
M`/2(A^JH/<`-L.PC]>PZ\M>^GE_AEW07"K>C:5%:5'R^UYXT]=#ZES?MQ7]]
M+*G'-)^BD3;.)GE>3*@+Z)?.BAT]0(SB;3QW#T;Q#CTZ^7O8F^VQ';,%[97$
MHH*AMTV.O_;.^FNZ-SQWA>>G(UOK97^F%UKEMD[;X#DI2O5N?A(UI8*M,S"4
MC)*/@?0;5VJ#IVW:BDU.1LT=+H+*J=D"BF3<1$"^'LOO797UG[N5WK&V-*U*
MPTJWU/3[JY;-.Z7K6D4AZLC(Z1D,C>Z*61_2`+&YB2&5'7FVY(Y-WLM[V>&6
M=T$K&%K0W+(0*`FIQ(#F@5K4TYK$8HR;',6C98BJ0_PP'<3`/[NMH[0]U=-L
M;.*]MGL<TM!&(/+@5J[@T.=\SF.!!!2[5BT'ND_.`S:N7[5"O.B/V\>\^!7<
M&<KMBM&B+SN)E1<+"D<Q0Z@$2D-Z=>@]I;JN-\[DU%]I#+<6K-,D$K(I.BYY
M>]G3C;+F:&O=E<X8U(8X4/!<4OK%NFV<1D<ULAF&4N&8"@-21S`PKAS"Y6RT
MK6&AWK,*K.Q+Q+K*JA(3P`LF81'Q.W5A.L-_H]X0'7DKO)-M2RBN;+]3ZA97
M3*AS)KOS`X\6.M<P^^(/I*Y]MUM](62&XBD8:4+8\/CS_P`B^."YVY\HY*%N
MD=$OZ.C]RG6!8?&?)M[P)([;?L\=;;\W=):R=V-V&T8YD?ZH@XO#_P"U'F&M
MI\6/@OT]V1(-`L0\@GY2[@*?[/UE.@Z^NZZ"6'L5@AJE7YZUV-^A%5VKPLI8
MI^4=&Z&T;"PC%>2E'[@^P]*#-BV.H8?H`NB*--Y?7+%\_P`O<K.=5]XM\RLH
M3W**YHPN*+%B+`TG?*=7L!4!96)K%<CK*>:BD%7RCQD1.1213,F5Q'%,)A.8
MX!5J.&%*A<;>>?98_D2.(L^0?&GEAB%[3V4EC&^V;.6$7V.JM*P,P[^;4AJV
MGOFLH@K-,9I212315Z!43>#TCN3I$JW##!2$?*3Y,FY1<&L1VB6D`?WK'K(^
M'LBF.8#.E+)0&[1@QE'6YC*&6L=45CI$YS`'4HY/]0ZBP<*%.4Z+%-$^>A_I
MIYM_O#B3_%"K:+)OM)F_R0(SG*XP?R!DN(UNXV1D:RR7&!/5;.]2ODJ\G;,2
MDL5F)HBR4V>C486.68=M$2KMG`E6`Q]RE';563J852*Y(YU<@N2_)J%X;^9[
M=9C`>!VV0B4W-%)PG#Q=%*A/HK)+55Q=+)*JVV2EL>*3?P3A5RBY.U!BL1\F
M4P$*<"H``JWBIA6!>/\`AKC1CB(Q;@NCPM%HT;N[391`'7<S$@Y33^)GYZ:<
MJ.)*Q3<B4A15>.EE53E`I0,!"E*$6F23Q3'?\R2VEU.*N"'38%1A&O(-(DQT
M@/:!TYQW<BPYEMO=#WTU@+O](^&BR9Q\4HO\NPZC%>!UH:M#(C(L^160@F2$
MV[Q57%;HJ[`R_P"\('CC)]&_[H:(_BGY=%@C1$:(C1$TKYS'(RP87XC2&,L:
MEDG^;>5,VE@7&4)`-G+^R.D;,F"5U?PL:S(=X^>)5U<6"!4@[GQLFW`OB(:+
M)H!./!:_QPY7TSC?@3$^!JOP8\Q<T%C"C0M2!0O%-\4DJ]:-0&>F%TS6WQ6G
MYE9R[6`?2=<V^B$5-:A1D,5904X"^:A%9%;TC).)\9#EB3[M(RK47E'NL?@#
M,,BX9G0FZN[7<&0)7HR3!PU$%54E%(I,Y3;^!:M3VFJ?N4Y%"E424(JDH4JB
M2J9BG353.4#)J)G*(E,0Y!`0$!$!`=1:*]R7Y9?M_$.B*YHBYGYA[_Y<<EB'
MI!G!#^S:TP8[_9KRW[Z8S>[+ND?D+7_'VJYSVV_SM8_=2?HI$TCC.[KPBR'P
M/8:.0V*5YV4W#TAMP\6ZK@JH-5-_0*12'#Z#:^,':;N%<[4U!D-DV.&>HI+E
M#Y:GFQSP[IFO`Q-:X?9%>A]P:0V\83+5S/16C?A`I7X21X+ORG7Q".0$K]3]
M5W"?1&+%K*+'DXZ):R0`U4:OR.#JEDI60(KT*(?E(IFZ#B)A,0/I5LS?T&F0
M%UZ?UQO746=#ISN,\-M'..F8Y@\NZUQ*'97Q?U<;#DD)<Y[!TSJ6DOF?^*_X
M?3H3F#FC*YY;B"VE,K6TJ'<2144%"OF1PKA).2M[V#4M,,C5T6CA[%U^Q)(P
M<@]6>$8O6\<B_CY)Q&M$7JH$*"2HD#Q`@%*`:_)J787L)!J^MZCMUVL6$.DL
MC?+;V5\&6<TKI!%*R%DT,[X(VRN#1TY,@Q#&M:`M2+=6Z76]O%>"WE?.2&OD
MCK(T`9@7%KFAQ+17$5]))JMOF)RBU*(:U:,8@QIL[&M)R*FV9UG,ZPE@!9FX
M>R2ZJIUY=1L[2.DNF8P'(F/2GML4-<ZUK7-@[0T:':.EV_0V-J%K%=6]U&7/
MNX;@9HWS3O<XON7,D:]DT;G!S6'+'0!K5MEO;:KJ-RZ^G?FU*)Y8YAH(W,P(
M:T`48"""T\">/-<:Y3OLND52*DI!*:;)DW9G=J!)ME&QORG$4_5_MB#94`\`
M343V'<IR@8!*'A7O7W,UBUA=H6HW+=0M@/Q9D/78YAKE?;RN_&M8:<&/80:M
M>T.!`[.VYHL#W"XA88I"<<OE-?0YH\I(\0?2#3%;_P"7\X^+R1DQ<I!*G^CX
MLH!U"<"B:=W`.HWB._2.V_CX:[-^;8=UNX^Z9PW*UVCVYI4FE;EV%3CZ>.*V
MSO&SIZ)8QDU/REW\Q.L:^PZ\\IEWSKLX6&$P-0^(N+'?5FGF[?X3#<"S;*[/
M65&>2\4UN4FH5)0%D6DDO),HHYA+TG;O7`@/\,VU631S]"=1P?B:MX$P]C/"
MU-2*A6L84JOTR,$A`1,[+"1R+1S)N"%$0^,EWI%'2YO2998P_3J+$FN*3+FE
MQ]9<J>+6;,$/"I&>WJD22-7<+]`A'7>'%.>I,B"BF_9!I:(QJ8Y@$!%+J+OL
M(Z*@T-5%R_EYN1#K%G);)_%JY*&B&N9X9>2A8U^/94CLMXK!^63ANE8Q.R\E
M:J=\10NW6=6*2)L([!JK4>*BJF5ZBTDT3YZ'^FGFW^\.)/\`%"K:+)OM+BC^
M6J_Z`<F/^]E=_P`/HO5*R?R67\_#@"3*^-PYD8Q@^_D;$L*G'Y>BXYF"CFYX
MF;',*=C410**CN8QN=<RJAQ*8QX518##LU2+HHP\EE/(D\Q%3-V/B\0\N3HN
MLKXFKY7.+IV3>`=[D'%,:5-N6&46<*"L_LN.DC)HFV$RCB(%%40$S=P?41XY
MA.B>8IQ3'F9Q'RCA*.,U0N;IHSMN-'KTX)-6F1*@O\UKB3E<P@5NSFA(K&N%
M1\$V[TYOHT6+30J--Y%7*\O%CD?DOB+G0KG'[++\\TB6+>TD-%*4S/-0.YA/
MTQ.$=F2+&JW&./\``%.;W3OV31,!$%RFU5J.%14*9OJ+21HBXRYZ<PJSPDXY
M6_,4HA'SER4*2M8EH;QV=NM?\E3("WKT&1-L(/CQ;581=R2B.QT6""H@('$@
M"5`J5U94'-A?5.K/;:R8QUK>UR"=V>/BQ<#&,;$ZBVJ\TRCA=G5=?`-9)15-
M'NF,IVRAU"([CHHF*Z`^2YX><K;[^ETR^#/+>IR]'JBY?[1#3&=[2X?1\O*(
MB50[91S%R",B4JA-Q`T"U.'W@T6?LM\2G]^L_P#6-_Q#_P">BP46[^9%XV!(
MUW"?*Z&8=:L(Z<X3R.ND0O4>&G#/;%0)!V)`ZA28S"<FS$YA^]()%^H-4+48
M>2=7\H7DU_F>X,XIFI:2!_?<7M38:R&*BA#/#S-%;M6D++.R]1EA/8:>M'O3
M*&#^(LJIL(B4=18N%"G1$ORR_;^(=%BKFB+3<A4Z-R#2+/2I<QDV%EB'<6LN
MF`&4:G7)_9GB11$`,JR=%(J4!\!,0-<-[A[)TSN/L;5=BZR2W3M4LI('.&+F
M%X\DC1]E$\-D;7#,T56XZ1J<^C:I!JEOC-!('@<C0X@^#A4'UJ/W>Z%=\+6U
MU7K2P7CGK593Y?)D34",FF@&$J,K"/3%!-PBLGL;8H]U$WNG`IRZ_G,[D]L]
M]=E-WR;<W;;R6NI0O=T+@-/0N8ZT;/:RD97-<,:`]2)U6O#7M7L/2-8TK=&G
M-O+![7Q.`S,KYF'FU[>((^)PQ%05LE,R:M!NDWPJ[+L2F59@8?$'P@)&RVPC
MN(M5#]X!_K)A]>MVV'W8U+:5V+Z1Q,MNTNBQK^-/EC=3GTW'J^M@]*_!JVWX
M[R,Q`>5YH[[GF/A'E^%*=$9@^&B["W%P/_N$:S;GW.(B84IJ.=[B.X^(]@=Q
M'7;>B]_8[;1M3MW.QN+6)IKSRW4$F/WO-<=N=K9[B%X'L/<?C8X?RK59K+*K
MR&^6'7Z@9.E7C$1/^65X1--^W+X_<5.DDJ`?UBF']X=<+U_OC=ZKH9TB)Q/0
MF,D)KP$@#9F#P<6QR`>EKSQ<5N=IMAL-UUZ>TT!WP8M/P5(]1'H2)/9>4L+E
M".:D<OEW+@",V+5%1T[7<+F`H),VR)%'"BBQA`.DA1$P_1OKI"6]UC<=Y'8,
M$UU=RRTAAC:Z1[GN-,L3&@N+GFE6M!S&A(J%RR*VM[&-TSRUC&M\SB0``.9)
MH,/24\/PYP9+8DIDI-VUJ+&XW=5FX=1AQ*9:#A&!51C(UT)=RDD%E'*B[@@"
M/;$Q"#[Q#:^W_N3=@=8[.;'NM>WC#T-ZZ\^-\D!H76MM$'="!]*@3.+WRS-!
M.4N9&?-&5YH[F;LM]QZI':Z<[/IMJ'`.Y/>ZF9P^U``:T\Z$\"$M&;)'.491
MEG''BJXUM^1SR;!NVC<LVVP4VGMHE7O?,I-Q)5FNV:6=/&8E3[34B"15@,;=
M8G2'5[876HISX*/SD+RSO-9RARNI'->Y9TXG2F6L:S4)+4&F&4R8&/*K%0#E
MTNSI<7&FJ1UTX-Q\>X,Y6%P+U==P=<5@5`@DJRJWAR3^>!I/D7*5-^IR8J&(
MZ?=T)D[>-;8:N-HN-9DX(K%F<LFX7ME:K4E%/U)$ZY/A0*Y*5(A#=X1,(!%B
M:<E@^0LMROC(ZO)\5J7@NU3#L\L2S/<XW6YU6+@2IHM!@W$5'TRL3KNP_$KF
M7!RF=PQ[94R=)S=8B0@IS49=QY$/F$/<NR/(-ER`XY4K+4AD:5RPVEZC)9%B
M_D%VD[`YLYGM?[%&,DP;-Y1T8$DA!0@(^X?K*)@-5GG'#DI"?&%QYA\>JK7N
M7,-Q?L,?'UAV,?DG#]IO,=8+#:6ZS4D:A8*/,U!"#8-9!N98[IVQ=)$2.0H)
MM-C"!8L3EY)O7FIQ5\UWGACTV&[9*<,L)8I<S<9/2\+5K;E6W6&PNH)U\;"M
MINQR%$:)!',WQ"..RT9MQ463()SF*7H$J"T8XI*.$'EY>:3Y>3FX-\0WSAWD
MVF9!=QDG;*+>)?*48V4EX=LNQ9R\'.QM-1D(:2,Q6%%41*X;+$*GUI"8A3`0
MEI&/%2":3^LIS'\"7+U<J$5=96`31OE6K$J[MU*;R+M`Z,K%1DK-P\*[G(91
M,XDZG#)$5"&$IB;>DL>>"B_W[R&>3=#Y7S&7>%^9,9XGHL1;4[SB*1L$[;&5
MQQ\\?$.Y?58K"*JDZS?P4.Z<+LV_>75([BE"HN$S?Q`-:K,/%,4^IQN4\QB*
ML,;7.5T?Q1ME.;Q,@5]D[#D_D2$N3R6;I)_*3.<?V"L?IU4D@L)@<JMWS,B(
M!U$1'[NHL#EY)!N?GE&<?><SQ2_@]?8=SRDT1;$RG4X]N]0LJ3$A"1K;(-8.
MLQ0LGR]-,$V[U%PTDVZ8%*"YTR%2`JUQ'J21878^<SQ,B6&.;71L)\]\<P#9
M!A7+@SRV.+,OM(IM_#;,YF3O,4FRL)F[?8I3.B.7GN@!WBH!OJJG*?!+W-<C
M_,XL+)1CCSRX*A2)A4ADT;!F3E?CU_6X]<P`!'#F&QY'/IR3:I&\132504.`
M>`EU%*-YE-VV#RF^?O*?D;BOD!S<Y*X;FXNB7>IV(<64=A<']?@JM!V.,G)2
MFTR.<1D%!PYII&-*BN]6%XZ<&V,X46Z2[599FC`)U#EQ%>8[>EK)0.)CKC=B
M^FSD$V8(YGR!:;T_R?%NI%JJG.'KM/AZ:[KD&]8'/T,WRSI^8/S01(<"],6(
MR\TV_P`$^!GF9^7<7(4=C^5X>YMK&49:,LEHB+?<\K5:=1L46V79$E(VU-Z#
M(JG.]:N!^(3=-W)3J!UE$AS'$]5):[C52&VHN#-VQGI$479D$!>)-E3KMTG(
MIE%PFW643146035$P$,8A#&*`"(`([:BP3-?/_CQYC/-&A9`X[5Z&XB8[PA8
M;>P<MK=,WC)5BR1.5JK6)K/5E=Q&I4)&"J<B\<Q[=1X1`SXY.DR2:W283FH6
M8+0:XKB+A[Y6_FF\![=+V[`^<>+%@B[61BWO6,K?(9,/2K@C&'4-'.GA$::V
M?1<Y'%75(W?LU4ER)JF3/W$A%/14N:>*D<X=?Y;DL>0+S.=;HM3R<H,@6QP>
M-K+,6ZFMNU).THU:(G)Z"KDJX!Y%D16535:E%!8YDP,H!0.:+3/@E.T16U?R
MS?9^(-$6N3=?@;,Q/&6.%B9^-..YF,S'M9)H)MA#J!!VDJF4^P_>``'UZV77
MMM[>W38.TO<UC9ZAIKN,5S#'-'7TY)&N;7T&E0OTVMY=V,HGLI9(9Q]<QQ:?
MC!"3<>/V#1$1_P#J6@^([_\`QQ@']"6NKC[M_8,FIV?M[^Y0?@+?/WRW7^T;
MS\Z[ZJJ&`,'@&P8HH@!]05YD&_T^.Q/'QT_AN[!?Z/V]C_T4'X"?OENO]H7?
MYQWU5\_Y?<&__DM"']M=8#_2GI_#?V#_`-'[>_N4'X"O[Y[L_:-Y^==]5;56
M<:X\I:YW52H]5KCM0.D[N(@X]F\$HAL)?BTD`<`00'Q`#``ZY?M7M;VVV/.;
MK9^@Z1IEVX4,EO:PQ2$'`CJ-8'T/HK1;=?:YK.IMR:C=7$[!R?(YP^(FGT%N
MVN>+:D:(D;/FRMGRRTPS'Q%E?6PS=S)2JYXI2.A8:%;-%'`RRC]^*)I%JX6!
M-%$6R:A%%%0`#AL.BM,*\DLFBB3USE&FM,E1V)5W[DMVE*^O96;$(]V9F:,;
MF6`XGD03^%3<&(V4.!!'[I/$0$0`2M#2O)*%HHC1$:(C1$D67,SUC#<9'/[%
M'6236FWA8R#90,.L\+(2ZNX-8U224%&+8.71@]PJRH',4!,4I@`=%0"4K*1C
MG22.JD*"ITDSJ(&.50R"AR%,=$QR>X<R1A$HB'@(AN&BBN:(C1$:(C1$:(C1
M$:(C1$:(C1%[$ORR_;^(=$5S1%;5_+-]GX@T1>/1$:(C1$:(C1$:(K2[A!H@
MN[=+$;M6J*KERNJ8"IH-VZ9EEUE##X%(DD03"/T`&B)L3'^8YEHOG3DG%4&0
MOCV4D56W>4DVT%!TO&E:,FE'-%95TFLH^F9,I$UCL6:*IR)HE65$@*$`]6H1
MP:G$6-RCW-&BKXZ;O6<?)UV(L/P*;9=_))EF&C5RVCD&C1(Z[U^=9V1%,B9-
MU%!#8`WU%A3&B2_$66U\JV_)+-:A)UU''4FWK+>PJ2;"7=OW:XKJR4.HY9-O
MAVJ[`4$SKI-W+A(AS@43"(`82$4"SELRP,=>XG%=+@RV_(,BP&:DFJT@,77Z
M?70,4GSJU2J360<-_B3G*5LU10477,8/NE,41(!A4\%E,59+;9,B)]R#$D7,
M5*W3M(LD>B[%^S2F8%P"2CB-?';M%'4:^0.15(QTDU"@82G*`E\2$47/>6,C
M7ZUYMQ_B?%!9=F[K*KZ\78C]X_I\988J+52091*\HG'OY`8%XZ343.H#4R3D
MRA.@3$]\"R``%2EHPAF-/,,+8W#F!/6+%3K._J=FA/CR2C5O),A_/82*:#8'
M31<`,`"*9#%,00\0V$2Q(HN?<]6QE/<C<.T!1F^G65!1<Y&?UR(23<R4_:W"
M9TZA#-T%E46P'2.@5PJJL=-!LU4465.4A1'560'E)2UXNS5-W;(F0L9VRC)T
MVRT5I%2:H,[$C9&3IC+@F=$BCM)BQ(F[(FX2,($`Q1ZC!X"7QBA``J$JUIN4
M15/EK9T1Y)3<ZNHUKU9AT2.YZ><H$!5R#)L=5%%%FR2$#N7;A1%HV(("JH7<
MH"4`JDMH>7[+=\K72@FI#:#A\?Q3$;)-'L"4PN6RRW;<QL*T^7MBQYA"/,<S
M@!4ZT5$S%\0Z1$A%!58?-O(M##\A`,BU1Q--I&R1T!+2SR1"$CV!WC=-^X+%
M@HT=.9UQ'1BA5G!DB%;("HFF9053]!2H;5;K0\@WNV6R=BYW$LW2:FWB6LM6
M+5+2C-=:<3=N"IHLWL4V(8T3)J-A%<[85#J-@#H5`IQ#10@`<5H&2^2[''UX
MIM42J;^9C[+8'D"[FP=&:N2K1JB#>1&N0!&CF2L7PCQR5N"@`BBX=E,@B=0Q
M3B4@%5BXWDS-.<G6C%KW%CM"R1<,UE8*-8VB-D7;M5T5LX!K:'2+<(:K$9QS
MH'#Q87#@C4"]L.ZH=,IRN7"O)*/@7+CS-%-?VMY6`K`LK+*U]%)"3^<1\F2+
M[!5)&-D!:,1<-175,D)@3Z1.F(E$0]!0BBW>PW=E#2K2LQK![9[@_:B_;5F'
M,W*X;1@*"B,S./W:B3"!AN^';*LN<#KJ`)$$U3@)0)3GR6@87RU-Y;<WUZM5
M&M>K%5LAZG#2!)CYNYG9:,`Y+"J55!NBP-'LU^V5%5(3=P#^.P@(`0@#UI==
M%%[$ORR_;^(=$5S1%;5_+-]GX@T1>/1$:(C1$:(C1$:(N<>64G9HS`]T)56,
M@\?RQ8^!>JQC5P\=QT%+/4FLW(%;M2*+G338&,F82E'I!7?P`-]%DVF;%:)&
MTUAD:B5##N/HF5KV#XQ&)5N]LE8E_`/+NVCU47R];KD=*(,Y9V>Q2B7=E)-5
M)-`J>Z:0J&,(%)6F/-+!GJYRV,L/6B<J$2Y=S;5@S@JVSBV2[D8]W*JHP[%X
M5LT244!O$$6[A0`HANF4OTZ*#$XK'<;J@K1\81$">&=Q:8"615>RX*(6*RRT
MFBF\GK#-1JI`5B!=R*ADVJ"QC.0:(D,L"9S=LHJNXI#*U+2N*<@<F)^6KTU8
M<FW*WM28U@F,2^?.[17P8*FK)F+Y-`S)O`LUW)2/55%4TVOPH@IL8"@)7B`.
M277COC"0Q)C<(ZTO6[BV3TM*W2[O4E"G;)3<P)5G2!''@15*.;(E(90/<.<I
MS![HAHL7&I\%S3A?)D6XM6=,UN8R=G;9>9OY#BVML(>2=R%AJM=!5A$(0RZ;
M867P3J2;ID>+F4*BT^'$RHE#;>K(C@.2Z2XZ8J?XGH2[>RK(N+G;)N1NEU7:
MG[Z",Q+""AHUJJ4!^(2C&Y03ZR@(**B<Q=P$-11QS'!(#B^:CJE9[;G_`"75
MKL6PYBR!)U&E-F=.FI>2K=0B0!K&"]8H-S/XPDV1@0@&!(3JE1)TE$HF'14X
MX#DNA,,X^DH66R#DNU-?@;EE>P$E7,6<Z2RU9J\<06=7KJZR0G2/(H,`!5X)
M#"0%S]`"()[B6)/(<%S6QRG>&TIR3OC6@6F2R)`/9:NUES)03TM;I^/:TD?X
M!-DY4(`R<A+2@'>JLFA3JO5A3.H)4"=9:LJ#`<DKO$.#F(?&OQLQ$R2,A;':
MMOL%BL":[*>LMJG%UEI$XQKI!-TE$13(K=!%PL)1=+=TZ:8(]!U(H[CX+$6"
MF2&7^4;!S/Q#\N.<%0;%TP&09.$HNR7J;.G(IBR.Y2(A(MHP$T#K&3$Y`4:%
M(;P/MH@-&^)78@CZ1,.WI$1_VB/KT6*X-KZ<E-V_*?*^Z56Q.T:0VDZQA>DN
M822^;JL8@BC,DVE#';B^(XFI!T8J1@3_`(0+KJ>@A3!5F>`:$G<O5;EBS!\C
M/NV$T\SAR9L;:-MTXQAY"3D*=#V4R[]Y&IM8]!P]1.TC!,0R12E.9RKTA^2F
M`%>)\`NY\:0PT?&41",JRK#M*U$.482`%<CB8=,6**BK1:9!`HMV]BGEBF<.
M4$C*E157Z.LQBF'46!Q*X(3RIDEMQ\O%NK].N">2K[9GR=_N<E`234T8:4DE
M8:#A*DB*!Y"1)"0'0@@9),&L;N<PB+@Y2FJSH,W@NX<!5L]/Q=6ZT2#7@F$4
MT228%D`,C-RW>12<R5@FX\Z93Q+N9F%G"R;50QUTFXI@KT*=29(L7<4LNBQ7
ML2_++]OXAT17-$7PH`F((!Z1V_I`=$7G[)_5[=$1V3^KVZ(CLG]7MT1'9/ZO
M;HB.R?U>W1$=D_J]NB*H)*!XAX#]8#MHB!24'Q'Q'UCOHB`24#Q#P'U#MHBI
MV3^KVZ(J]M7;;?P^KJ\/9HB13.S;)TG0I^K8PK2<K.6>'>Q`S3J?BX9G`H/B
M_"NUNAV?XMV\49**`D"92D*80,8X;;"5%*U*SF%ZJ[I>+*347,(M7G-=@FD6
M\CEGT<_$SY$G5(OBNHM=PT62D7ZBJQ1W*?8_OE*.X:(<2E.[)_5[=%%7MJ[B
M._B.VX]0[CMZ-_KVT14[)_5[=$5>VKX>/H]'O>C]GU:(@4E!\1\1^L1WT1':
M4'8!]`>CQ]'[-$5.R?U>W1%7MJ[[[^/U]7C[=$0":H;B`["/I$#>G]NB*G9/
MZO;HBKVU=]]_';;?J'?;ZM_JT14[)_5[=$1V3^KVZ(O0F`E(`#Z0W_I$=$7W
MHB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1
- -HB-$1HB-$1HB-$7_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
